RNAi therapeutics company
reported a widened second-quarter loss late Thursday but upped year-end cash estimates.
Alnylam recorded a net loss of $12.7 million, or 34 cents a share, compared with $9.9 million, or 31 cents a share, in the year-prior period. That's including a 5-cent-per-share stock-based compensation expense in both quarters.
Analysts surveyed by Thomson Financial had expected a loss of 24 cents a share on revenue of $7.1 million.
Alnylam reported revenue of $9.1 million, compared with $6 million during the year-ago quarter. This year's revenue included $4.4 million related to Alnylam's collaborations with
, $2.8 million from the National Institutes of Health for Ebola, and $1.9 million of expense reimbursement and amortization revenues from
, research reagent and services licensees, and other sources.
The company increased its year-end 2007 cash guidance to greater than $435 million from greater than $180 million to reflect its alliance with
. Alnylam also announced that it has completed the previously announced
deal with the Swiss drugmaker.
The company's shares closed up 2.1% at $25.98 and rose another 0.9% to $26.20 in postmarket trading.